



**FOR IMMEDIATE RELEASE**

## **Trevi Therapeutics Announces Incorporation and Phase 2 Development of T111**

*Company developing its lead compound in chronic uremic pruritus*

**SANDY HOOK, CT, September 26, 2011**—[Trevi Therapeutics, Inc.](#) announces its incorporation and the initiation of development of [T111](#) for chronic uremic pruritus. The Company is seeking orphan drug designation for this compound in both the US and Europe, and is also prosecuting patent applications.

[Trevi](#) was founded in 2011 as a drug development company focused on developing compounds primarily for orphan diseases with unmet medical needs. The company was co-founded by Jennifer L. Good and Thomas R. Sciascia, MD, the former executive management team at Penwest Pharmaceuticals, which was acquired by its partner, Endo Pharmaceuticals, in the fourth quarter of 2010. Ms. Good will serve as Trevi's President and CEO and Dr. Sciascia will serve as the Company's Chief Medical Officer.

Trevi's lead compound, T111, is entering Phase 2 development and is targeted at treating chronic uremic pruritus, a persistent form of itching in patients on hemodialysis. Currently, there are no approved drug therapies in either the US or Europe for chronic uremic pruritus, of which the Company believes there are approximately 170,000 patients in the US and 135,000 patients in Europe.

"Trevi's development strategy reflects our belief in the value of orphan drug development," Ms. Good said. "There are vast unmet medical needs in orphan diseases, and we believe small, focused drug development companies like Trevi are uniquely suited to advance these compounds efficiently to points of proof of concept and value creation. We have been working diligently to complete the necessary steps to commence clinical trials, which we plan to initiate in the first quarter of 2012."

### **About Trevi Therapeutics, Inc.**

[Trevi Therapeutics, Inc.](#) is a drug development company founded in 2011 to develop compounds, primarily for orphan diseases with unmet medical needs. The Company's lead compound, T111, is entering Phase 2 development and is targeted at treating chronic uremic pruritus, a persistent form of itching in kidney dialysis patients. The Company is seeking orphan drug designation in the US and Europe and is also prosecuting patent applications. The Company also intends to evaluate other orphan opportunities to add to its development pipeline. For additional information, visit [www.trevitherapeutics.com](http://www.trevitherapeutics.com).

###

**Media contact:** Laura Brophy, 203-331-7618, [mediarelations@trevitherapeutics.com](mailto:mediarelations@trevitherapeutics.com)